Ocrelizumab for Treating MS Patients

Wendy Henderson avatar

by Wendy Henderson |

Share this article:

Share article via email

In this video from the Healthcare Channel, Dr. Jerry S. Wolinsky talks about the results of an Ocrelizumab (Ocrevus) clinical trial for primary-progressive multiple sclerosis (PPMS) patients.

MORE: What the world is saying about Ocrevus.

The neurologist, from the University of Texas Health Service Center in Houston, begins by explaining the difference between relapsing MS and progressive MS and that women tend to have the relapsing form and men the progressive form. Until recently, medications and treatments have only worked for relapsing MS.

Ocrelizumab is a monoclonal antibody that targets B-cells, and is the first approved treatment for the use in PPMS. Wolinsky talks about two published papers on the comparison of Ocrelizumab and interferon for relapsing MS and the effectiveness of Ocrelizumab in slowing down the progression of PPMS.

MORE: Four ways Ocrevus can improve your life. 

Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Dancing Doodle

Did you know some of the news and columns on Multiple Sclerosis News Today are recorded and available for listening on SoundCloud? These audio news stories give our readers an alternative option for accessing information important for them.

Listen Here